Novartis Revamps U.S. Pharma Unit, With New CEO Andre Wyss
Executive Summary
Novartis is reorganizing its U.S. pharmaceutical business, effective May 1, a move that includes the departure of Ludwig Hanston, who ran the unit for the past two years, and the elimination of nearly 400 positions mostly at U.S. headquarters, the company's Global Pharma CEO David Epstein told employees in a memo distributed on April 13
You may also be interested in...
Novartis Sales Rise 25%; Jimenez Talks Up U.S. Commercial Restructuring In Interview
Novartis sees no need to change its 2010 guidance based on health care reform and maintains its forecast for mid-single-digit growth.
Novartis' Gilenia Extension Trial Data Support Efficacy Of Low-Dose Version
Two-year data on the oral multiple sclerosis drug show sustained efficacy, and potential benefits of switching from interferon-1a, Novartis says.
Novartis Splits Chair and CEO Positions, Names Joe Jimenez CEO
The news eclipses reports of a strong 2009, in which Novartis received 30 major regulatory approvals, and saw sales grow across major divisions